Stocks · News reference
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Beam Therapeutics announced management participation in three major investor conferences in September 2026. The company also reported progress on its BEAM-302 trial in Alpha-1 Antitrypsin Deficiency, with dosing completed for adult and adolescent patients and updated data selected for presentation at the European Respiratory Society Congress 2026.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.